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Background — The benefit of preoperative bridging in surgical 
patients with continuous anticoagulant therapy is debatable, and 
drawing of meaningful conclusions may have been limited by 
mixed procedures with different thromboembolic and bleeding 
risks in most published studies.
Patients and methods — This was an observational cohort treat-
ment study in consecutive primary unilateral total hip and knee 
arthroplasty patients between January 2010 and November 2013 
in 8 Danish fast-track departments. Data were collected prospec-
tively on preoperative comorbidity and anticoagulants in patients 
with preoperative vitamin K antagonist (VKA) treatment. We 
performed 30-day follow-up on in-hospital complications and 
re-admissions through the Danish National Patient Registry and 
patient records.
Results — Of 13,375 procedures, 649 (4.7%) were in VKA 
patients with a mean age of 73 (SD 9) years and a median length of 
stay of 3 days (IQR: 2–4). Preoperative bridging was used in 430 
(67%), while 215 (33%) were paused. Of 4 arterial thromboem-
bolic events (ATEs) (0.6%), 2 were in paused patients and 2 were 
in bridged patients (p = 0.6). Of 3 venous thromboembolic events 
(VTEs) (0.5%), 2  were in paused patients and 1 was in a bridged 
patient (p = 0.3). Of 8 major bleedings (MBs) (1.2%), 1 was in 
a paused patient and 7 were in bridged patients (p = 0.3), 5 of 
whom received therapeutic bridging. Similar results were found 
in a propensity-matched cohort.
Interpretation — In contrast to recent studies in mixed surgical 
procedures, no statistically significant differences in ATE, VTE, 
or MB were found between preoperative bridging and pausation 
of VKA patients. However, the higher number of thromboembolic 
events in paused patients and the higher number of major bleed-
ings in bridged patients warrant more extensive investigation.

Perioperative management of patients with preoperative vita-
min K antagonists (VKAs) is a challenge in elective surgery. 
Guidelines have been drawn up to help balance the risk of 
arterial thromboembolic events (ATEs) such as ischemic 
stroke, transient ischemic attack (TIA), and peripheral arte-
rial embolism with the risk of procedure-related bleeding, in 
order to identify which patients may benefit from preopera-
tive heparin bridging (Douketis et al. 2012, Kristensen et al. 
2014). Current recommendations for perioperative manage-
ment of anticoagulants include individual risk assessment 
by clinicians specializing in periprocedural antithrombotic 
treatment, the surgeon, and the anesthetist (Douketis et al. 
2012, Kristensen et al. 2014). However, the level of evi-
dence is generally low (Douketis et al. 2012) and the benefit 
of preoperative bridging with low-molecular-weight heparin 
(LWMH) remains debatable (Douketis 2012, Spyropoulos 
2012). The risk of ATE and bleeding depends on the surgi-
cal procedure, the indication for anticoagulant treatment, and 
patient-related risk factors. In patients with atrial fibrillation, 
patient-related risk factors are incorporated into risk scores 
such as the CHADS2 (Gage et al. 2001) or more recently 
the CHA2DS2-VASc (Lip et al. 2010), which may aid clini-
cal decision making (Douketis et al. 2012, Kristensen et al. 
2014). Procedure-related risk is more problematic, as defini-
56 Acta Orthopaedica 2017; 88 (1): 55–61
tions of procedures with a high risk of major or critical bleed-
ing differ (Douketis et al. 2012, Daniels 2015). 
Furthermore, most published studies, including several 
recent large randomized and observational trials (Clark et al. 
2015, Douketis et al. 2015a, b), have been in selected patients 
with limited information on perioperative care, and have 
involved mixed surgical procedures with substantial varia-
tion in postoperative complication rates and risk of bleeding 
(Siegal et al. 2012). For example, 2 studies involving almost 
3,700 patients included only about 9% major surgical pro-
cedures (Clark et al. 2015, Douketis et al. 2015b). Total hip 
(THA) and knee arthroplasty (TKA) are often considered to be 
“high-risk” regarding venous thromboembolic events (VTEs) 
(Falck-Ytter et al. 2012) and bleeding (Douketis et al. 2012, 
Douketis et al. 2015b). They are common procedures, with a 
high number of elderly patients having multiple comorbidi-
ties, including conditions requiring VKA treatment. Over the 
last 2 decades, the development of enhanced recovery proto-
cols or “fast-track” surgery, have reduced postoperative mor-
bidity and hospitalization after THA and TKA (Kehlet 2013). 
In this context, the incidence of both ATE and VTE may be 
reduced compared to conventional perioperative care (Husted 
et al. 2010a, Jorgensen et al. 2013, Khan et al. 2014, Jorgensen 
and Kehlet 2016). However, the incidence of ATE and major 
bleeding (MB) in patients with preoperative VKA treatment 
has not been specifically evaluated in fast-track THA and 
TKA, and no studies on the potential benefits and harms of 
preoperative heparin bridging have been performed in a stan-
dardized fast-track setting.
We therefore wanted to investigate the occurrence of ATE, 
VTE, and MB in patients with preoperative VKA treatment 
with and without preoperative bridging.  
Patients and methods
We initially included all primary unilateral elective THAs 
and TKAs performed in 8 participating departments between 
January 1, 2010 and November 1, 2013. Information on pre-
operative patient characteristics (including use of any type of 
anticoagulant therapy, use of walking aids, and pharmacologi-
cally treated heart disease) was obtained through a patient-
reported questionnaire, which has been described in detail 
elsewhere (Jorgensen and Kehlet 2013). Data on the specific 
type of anticoagulant therapy was acquired from the Danish 
National Database on Reimbursed Prescriptions (DNDRP). 
The DNDRP registers all prescriptions qualifying for reim-
bursement dispensed at Danish pharmacies, including medi-
cations distributed through nursing homes (Johannesdottir et 
al. 2012).  During the study period, dabigatran, rivaroxaban, 
and apixaban qualified for reimbursement in > 99.5% of all 
dispensed prescriptions while adenosine diphosphate (ADP) 
receptor inhibitors qualified in 97.4% of cases and dipyridam-
ole in 99.9% of cases (Danish statistics: www.medstat.dk). 
Acetylsalicylic acid (ASA) qualified for reimbursement in 
only 87.5% of dispensed prescriptions, and consequently 536 
patents (3.9%) who had no prescriptions on anticoagulants but 
who reported using anticoagulants in the preoperative ques-
tionnaire were considered to have used ASA.   
In patients with confirmed VKA, we registered the fol-
lowing data using the medical records: indication for VKA, 
date and value of INR (international normalized ratio), and 
preoperative management (preoperative bridging/pause). The 
CHA2DS2-VASc was used for thromboembolic risk stratifi-
cation of patients with atrial fibrillation, and was calculated 
using the patients’ preoperative questionnaires and medical 
records for information on diabetes, hypertension, previous 
stroke/TIA, heart failure, and vascular disease. 
Information on index admission and 30-day follow-up was 
acquired through the DNPR. DNPR records all admissions to 
Danish hospitals, allowing a follow-up of > 99% (Andersen et 
al. 1999). Re-admissions were defined as requiring at least 1 
night in hospital and being (potentially) related to surgery, as 
previously described (Jorgensen and Kehlet 2013). Any proce-
dure requiring > 4 nights in hospital and all admissions after sur-
gery were evaluated regarding morbidity using discharge papers 
and any case of suspected ATE (ischemic stroke, TIA, and 
peripheral embolism but excluding myocardial infarction), VTE 
(deep venous thrombosis (DVT) or pulmonary embolism (PE)), 
or major bleeding (MB) was followed by review of the entire 
medical records and other available material (autopsy reports, 
computed tomography scans, ultrasound, etc.). ATE, VTE, and 
MB were defined according to ISTH criteria (Schulman et al. 
2010), and follow-up was done 30 days postoperatively as rec-
ommended internationally (Spyropoulos et al. 2012).
All the participating departments used  similar fast-track 
protocols, including spinal anesthesia, multimodal opioid 
sparing analgesia, early mobilization, and discharge to own 
home (Husted et al. 2010b). In 6 of the participating depart-
ments, preoperative bridging of high-risk VKA patients was 
initiated 3–4 days before surgery with therapeutic doses of 
LMWH. Doses were reduced on the day before surgery, with 
the last dose being given 12–24 hours preoperatively. VKA 
was resumed in the evening of surgery or on the day after, 
depending on adequate hemostasis, and with postoperative 
bridging using prophylactic doses on the first postoperative 
day followed by therapeutic doses until INR > 2.0. Patients 
who did not receive preoperative bridging were bridged post-
operatively with prophylactic doses until INR > 2.0. 
2 departments followed the same routines but used only 
prophylactic doses in all patients. (For details of the periop-
erative regimens, see Supplementary data). Any patient with 
ASA or ADP antagonist treatment was paused 5–7 days pre-
operatively. 
Statistics
No pre-study power calculation was conducted, as all pri-
mary elective unilateral procedures available in the LCDB 
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were included. Distribution of data was analyzed using visual 
inspection of histograms and q-q plots. Mean and standard 
deviation (SD) are reported for parametric data and median 
with interquartile range (IQR) is given for non-parametric 
data. Comparisons of means for continuous parametric data 
and medians for non-parametric data were done using Stu-
dent’s t-test for independent samples and the Mann-Whitney 
U-test, respectively. Proportions were compared using Fish-
er’s exact test. Proportions are reported as percentage with 
95% confidence interval (CI). Propensity score (PS) was cal-
culated using a logistic regression model including  character-
istics previously related to postoperative outcomes or throm-
boembolic/bleeding risk: age; gender; joint of surgery; use of 
walking aids; BMI; smoking; alcohol use > 24 g/day; living 
with other/alone/in institution; anemia; diabetes; treatment for 
cardiac, pulmonary or psychiatric disease; previous cerebral 
stroke; previous VTE; hypertension; and hypercholesterol-
emia. PS matching was done using a greedy matching algo-
rithm with a caliper of 0.2 and discarding patients with a PS 
outside the area of common support. Covariance balance was 
assessed using standardized differences (STDs) (Austin 2009) 
with an STD of > 0.2 chosen to indicate major imbalance. A 
weighted analysis was done using the Mantel-Haenszel sta-
tistic, and common odds ratio (OR) estimate was used for the 
PS-matched analysis. Statistical analysis was performed using 
SPSS version 22 with a PS-matching add-on (Thoemmes 
2012; http://www.vassarstats.net/prop1.html). 
Ethics and registration
No approval from the regional ethics committee was required, 
as this was a non-interventional study. Permission to review 
and store patient records without obtaining informed consent 
was acquired from the Danish Data Protection Agency (entry 
no. 30-0623) and the Danish National Board of Health (entry 
no. 3-3013-56/1/HKR).
The study was based on the Lundbeck Foundation Center 
database (LCDB), which is a prospective database of preop-
erative patient characteristics in patients undergoing elective 
THA or TKA in Danish orthopedic departments that par-
ticipate in the Lundbeck Foundation Center for Fast-track 
Hip and Knee Replacement Collaboration. It is registered 
at ClinicalTrials.gov as an ongoing study registry (identifier 
NCT01515670).
Results
The initial cohort consisted of 13,775 procedures (7,222 THAs 
and 6,553 TKAs) with a median length of stay (LOS) of 2 days 
(IQR: 2–3). The mean age of patients was 68 (SD 11) years and 
58% were women. After evaluation of discharge records fol-
lowed by evaluation of the complete medical records, 27 ATEs 
(0.2%, CI: 0.1–0.3), 61 VTEs (0.5%, CI: 0.4–0.6), and 87 MBs 
(0.6%, CI: 0.5–0.8) were found within 30 days after surgery.
649 patients (4.7%) had preoperative VKA treatment with a 
median LOS of 3 days (IQR: 2–4) (Figure).  The most common 
indication for VKA was atrial fibrillation (76%), followed by 
previous VTE (12%) (Table 1), and the mean INR prior to 
surgery was 1.2 (SD 0.2). Of the VKA patients, 430 (67%) 
received preoperative bridging and 215 (33%) were paused, 
while information was unavailable for 4 patients (0.6%). 4 TEs 
(0.6%, CI: 0.2–1.6), 2 in bridged patients (0.5% CI: 0.1–1.7) 
and 2 in paused patients (0.9%, CI: 0.3–3.3; p = 0.6, Fisher’s 
exact test) occurred within 30 days of surgery. Of the ATEs in 
bridged patients, 1 was in a patient receiving therapeutic doses 
of LMWH (0.4%, CI: 0.06–2.1) and 1 was in a patient receiv-
ing prophylactic doses of LWMH (0.6%, CI: 0.1–3.4; p = 1.0). 
Of 3 VTEs (0.5%, CI: 0.2–1.4), 2 (0.9%, CI: 0.3–3.3) were in 
paused patients and 1 (0.2%, CI: 0.04–1.3) was in a bridged 
patient (p = 0.3) (Table 2). The rates of VTEs were similar 
regardless of whether there were therapeutic doses of LMWH 
(0.4%, CI: 0.06–2.1) or prophylactic doses of LMWH (0.0%, 
CI: 0.0–2.3; p = 1.0). Finally, we found 8 MBs (1.2%, CI: 0.6–
2.4), of which 1 (0.5%, CI: 0.08–2.6) was in a paused patient 
and 7 (1.6%, CI: 0.8–3.3; p = 0.3) were in bridged patients. 6 
of the 7 MBs in bridged patients occurred in those receiving 
therapeutic doses of LMWH (2.2%, CI: 1.0–4.8) and 1 was in 
a patient receiving prophylactic doses of LMWH (0.6%, CI: 
0.1–3.4; p = 0.3) (Table 2). 
Flow chart of the study population. DNHR: the Danish National Health 
Registry; THA: total hip arthroplasty; TKA: total knee arthroplasty; 
LCDB: the Lundbeck Foundation Center for Fast-track Hip and Knee 
Replacement database; VKA: vitamin K antagonist.
Total number of 
procedures in DNHR
n = 15,645
Excluded (n = 1415):
– age ≤ 18 years or foreign social security 
   number, 12
– simultaneous or staged procedures within 
   3 months, 449
– other surgery in same hip/knee < 3 months 
   previously or due to fracture, 867
– surgery due to severe congenital disorder, 
   infection or cancer, 87
Primary elective unilateral THA/TKA
n = 14,230
Total number of procedures 
fitting criteria and with 
completed LCDB questionnaire
n = 13,775
(97% of eligible procedures)
Primary elective unilateral THA/TKA
with VKA-treatment
n = 649 (4.7% of 13,775)
Excluded: Not in LCDB
n = 455 (3%)
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PS matching was possible in 288 bridged 
and in 182 paused VKA patients. There were 
2 ATEs in both bridged (0.7%, CI: 0.2–2.5) 
and paused patients (1.0%, CI: 0.3–3.6; OR = 
0.8, CI: 0.1–4.6; p = 0.8), and only 1 VTE in 
a bridged patient (0.4%, CI: 0.06–1.9; OR not 
available). Finally, there were 3 MBs (1.0%, 
CI: 0.4–3.0) in the 288 bridged patients and 1 
(0.5%, CI: 0.09–2.8; OR = 0.4, CI: 0.1–3.1; p = 
0.4) in the 198 patients who were paused.   
Discussion
This procedure-specific study of VKA-treated 
patients undergoing fast-track THA or TKA 
raises several questions regarding the benefits 
and consequences of preoperative bridging 
compared to pausation. Thus, although there 
were no statistically significant differences in 
ATEs, VTEs, and MBs between the 2 groups, 
the incidence of MBs was 3 times higher in 
bridged patients than in paused patients, and 
even higher when the comparison was done 
with therapeutically bridged patients. On the 
other hand, although the occurrence of ATEs 
and VTEs was rare, 2 of 4 ATEs and 1 of 3 
VTEs were fatal, which highlights the impor-
tance of preventing these critical events.
The lack of any difference in ATEs between 
bridged and paused VKA patients has been 
found in previous studies on mixed surgical 
procedures, with few major orthopedic proce-
dures and limited information on perioperative 
care (Clark et al. 2015, Douketis et al. 2015a). 
It has been argued that preoperative bridging 
reduces the risk of ATE to the same levels as in 
those patients who only need pausation (Siegal 
et al. 2012, Spyropoulos 2012), but a recent 
randomized study and a metaanalysis found 
no benefit of preoperative bridging in patients 
with atrial fibrillation (Douketis et al. 2015b, 
Ayoub et al. 2016). We found more ATEs in 
the paused patients, although this was not sta-
tistically significant. That there were numeri-
cally more ATEs in the paused patients could 
possibly be due to a large fraction of paused 
patients having similar risk profiles to those 
who were bridged.  However, it must be kept 
in mind that international guidelines on peri-
operative risk evaluation are conflicting. Thus, 
if we had adhered to the ESC/ESA (Kristensen 
et al. 2014) instead of the American College 
of Chest Physicians (ACCP) recommendations 
Table 1. Preoperative characteristics of VKA patients
  PS-matched PS-matched
 All VKA bridged paused
 patients VKA patients VKA patients
Characteristic (%) n = 649 n = 288  n = 182 STD
Age, mean (SD) 73 (8.6) 73.9 (8.2) 73.9 (7.7) 0
Sex
    Male 357 (55.0) 158 (54.9) 105 (57.7) 0.056
    Female 292 (45.0) 130 (45.1) 77 (42.3) 
Joint surgery
    THA 338 (52.1) 149 (51.6) 98 (53.8) 0.044
    TKA 311 (47.9) 139 (48.4) 84 (46.2) 
Living
 with spouse/relatives 406 (62.6) 179 (62.1) 115 (63.2) 0.023
 alone 239 (36.8) 109 (37.9) 67 (36.8) 0.023
 at institution 3 (0.5) 0 (0.0) 0 (0.0) 0
 missing 1 (0.2) – – –
Use of walking aids 231 (35.6) 105 (36.5) 68 (37.4) 0.019
 missing 18 (2.8) – – –
BMI, mean (SD) 28.7 (5.1) 28.6 (5.2) 26.8 (5.2) 0.019
 missing 2 (0.3) – – –
Smoker 64 (9.9) 26 (9.1) 18 (9.9) 0.027
 missing 7 (1.1) – – –
Alcohol use > 24 g/day 61 (9.4) 29 (10.2) 22 (12.1) 0.060
 missing 6 (0.9) – – –
Antihypertensive treatment 533 (82.1) 247 (85.7) 157 (86.3) 0.017
 missing 1 (0.2) – – –
Anticholesterol treatment 416 (64.1) 186 (64.6) 115 (63.2) 0.029
 missing 10 (1.5) – – –
Diabetes mellitus
 insulin-dependent 26 (4.0) 6 (1.9) 3 (1.6) 0.023
 non-insulin-dependent 81 (12.5) 36 (12.6) 24 (13.2) 0.018
 missing 1 (0.2) – – –
Preop. anemia a 119 (18.3) 48 (16.8) 33 (18.1) 0.034
 missing 7 (1.1) – – –
Pharmacologically treated: 
 Cardiac disease 559 (86.1) 260 (90.1) 167 (91.8) 0.059
     missing 0 (0.0) – – –
 Pulmonary disease 58 (8.9) 25 (8.8) 18 (9.9) 0.038
     missing 8 (1.2) – – –
 Psychiatric disease 108 (16.6) 40 (13.7) 25 (13.7) 0
     missing 4 (0.6) – – –
Previous stroke/TIA 111 (17.1) 40 (13.7) 26 (14.3) 0.017
 missing 0 (0.0.) – – –
Previous VTE 161 (24.8) 57 (19.8) 38 (20.9) 0.027
 missing  0 (0.0.) – – –
ADP2 inhibitors 6 (0.9) 4 (1.4) 0 (0.0) –
Dipyradimole  3 (0.5) 1 (0.3) 0 (0.0) –
Acetylsalicylic acid 114 (17.6) 40 (13.7) 22 (12.1) –
Bridging
 therapeutic 268 (41.3) 172 (59.9) – –
 prophylactic 162 (25.0) 116 (40.1) – –
 pausation 215 (33.1) – 182 (100.0) –
 missing 4 (0.6) – – –
Indication for VKA treatment
 atrial fibrillation 495 (76.3) 254 (88.2) 163 (89.6) –
 previous VTE 84 (12.9) 24 (8.2) 13 (7.1) –
 heart valve 44 (6.8) 3 (1.1) 2 (1.1) –
 genetic disposition  19 (2.9) 6 (2.2) 3 (1.6) –
 other causes 7 (1.1) 0 (0.0) 0 (0.0) – 
CHA2DS2-VASc, mean (SD) b  3.7 (1.6)) 3.7 (1.5) 3.6 (1.7) –
PS: propensity score; a standardized difference (STD) of > 0.2 was chosen as being 
indicative of imbalance; THA: total hip arthroplasty; TKA: total knee arthroplasty; BMI: 
body mass index; TIA: transient ischemic attack. 
a women : 12 g/dL; men: 13 g/dL.
b Patients with atrial fibrillation only.
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(Douketis et al. 2012), 1 of the paused patients who suffered 
from an ATE should have received preoperative bridging. Fur-
thermore, the ESC/ESA recommendations use CHA2DS2-
VASc and the ACCP recommendations use CHA2DS for 
patients with atrial fibrillation, potentially increasing the 
number of patients who qualify for bridging when adhering 
to ESC/ESA recommendations. This reflects the increased 
complexity of perioperative VKA treatment, as opposed to the 
new direct oral anticoagulants (DOACs), where the main issue 
is prolonged half-life in patients with reduced renal function 
(Douketis et al. 2012). However, although the use of DOACs 
is on the increase, it seems likely that perioperative VKA treat-
ment will remain a clinical problem for a considerable time.
We found similar VTE rates in bridged and paused VKA 
patients. This is in accordance with the results of a previous 
retrospective study of 1,178 patients who mainly received 
VKA because of recurrent VTE (Clark et al. 2015). However, 
the study included a wide range of mainly minor procedures, 
only about 14% of which were orthopedic, and with major dif-
ferences in baseline risk of VTE between paused and bridged 
patients.
Increased bleeding risk in bridged VKA patients is well doc-
umented (Siegal et al. 2012, Douketis et al. 2015a, b, Clark et 
al. 2015, Ayoub et al. 2016, Breen et al. 2016), and it has been 
argued that the risk of postoperative bleeding associated with 
bridging may be understated (Douketis 2012). Furthermore, the 
increased bleeding risk may be related to the use of therapeutic 
doses of LMWH rather than prophylactic doses (Pengo et al. 
2009). In THA and TKA, even “less” severe MBs may lead 
to serious complications due to a subsequent increased risk of 
reoperation, immobilization, and prosthetic infection (McDou-
gall et al. 2013, Leijtens et al. 2014). In the present study, MBs 
occurred in less than 2% of bridged patients, despite the fact 
that THA and TKA may be considered to be high-risk proce-
dures (Douketis et al. 2012). This contrasts with 2 other small 
cohort studies in THA and TKA, which had major bleeding 
rates of 92% and 33% (Leijtens et al. 2014, Haighton et al. 
2015). The difference may be due to different definitions of 
bleeding and methods of data collection, and allowances must 
be made for subjectivity, even within the ISTH recommen-
dations. Although MBs were rare in our study, we did find a 
considerable numerical increase in MBs in the bridged patients 
compared to the paused patients, especially when the compari-
son was done with bridged patients who received therapeutic 
doses. Consequently, the lack of statistical significance may 
have been due to the limited sample size. Finally, the MBs in 
our study were highly clinically relevant, as they all resulted in 
death, surgical interventions, or repeated blood transfusions. In 
this context, almost one-third of the registered thromboembolic 
or bleeding events were fatal. This contrasts with most of the 
recent trials in mixed patients, where ATE-, VTE-, and MB-
related mortality has been extremely rare (Dunn et al. 2007, 
Douketis et al. 2015a, b). Consequently, whether the results of 
studies in selected mixed patient populations can be uncriti-
cally extrapolated to specific major surgical procedures in 
everyday patients seems questionable.    
The most important limitation of the present study was 
the rarity of events, combined with less than 5% of the ini-
tial cohort using VKA.  Thus, despite the fact that we initially 
included almost 14,000 patients, our study remained at risk of 
being subject to type-II error. This is a common problem in 
bridging studies, including RCTs (Dunn et al. 2007, Douketis 
et al. 2015b), and highlights the need for international collabo-
ration to achieve the necessary number of events, especially 
in procedure-specific studies. Another limitation, potentially 
influencing the relatively low incidence of MB, may be that 
we only evaluated the medical records of patients who were 
noted as having a clinically relevant bleeding episode in their 
discharge papers. This, as well as a lack of transfusion data, 
may lead to an underestimation of bleeding episodes, but on 
the other hand it ensured that the bleedings were considered 
of clinical importance. With regard to whether the bridged 
patients received therapeutic or prophylactic doses, we 
assumed that all patients were treated according to the depart-
Table 2. Types and timing of ATE, VTE, and major bleeding
 Preoperative Any Prophylactic Therapeutic
 pause  bridging bridging bridging
Events n = 215  n = 430 n = 162 n = 268
Arterial thromboembolic event 2 (0.9%) 2 (0.5%) 1 (0.6%) 1 (0.4%)
 Arterial embolism 1 (day 15, fatal)
 Stroke 1 (day 1, fatal) 2 (day 2, 2) 1 (day 2) 1 (day 2)
Venous thromboembolic event 2 (0.9%) 1 (0.2%) 0 (0.0%) 1 (0.4%)
 Deep venous thrombosis; 2 (days 11,23)
 Pulmonary embolism  1 (day 7, fatal)  1 (day 7, fatal)
Major bleeding 1 (0.5%) 7 (1.6%) 1 (0.6%) 6 (2.2%)
 Cerebral hemorrhage  1 (day 3, fatal) 1 (day 3, fatal)
 Retroperitoneal bleeding  1 (day 10)  1 (day 10)
 Hematoma with transfusion/
    surgical intervention 1 (day 22) 5 (days 1, 7, 9, 10, 20)  5 (days 1, 7, 9, 10, 20)
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mental guidelines, as no-patient level data were available. 
Furthermore, it may be questioned whether some of the MB 
episodes were related to other drugs, e.g. NSAIDs, which are 
common in this population. Finally, as our study was observa-
tional, there was a risk of confounding by indication, which 
is why we performed a secondary analysis on a PS-matched 
dataset—which showed similar results. 
The study had several strengths, including a large well-
described consecutive unselected cohort of specific major sur-
gical procedures with similar fast-track protocols, prospective 
recording of preoperative characteristics supplemented with 
nationwide data on reimbursed prescriptions (Johannesdot-
tir et al. 2012), and complete 30-day follow-up through the 
DNPR. Also, all participating departments were large regional 
or university hospitals that contributed about one-third of all 
primary THA and TKA procedures in 2012 (The Danish Hip 
Arthroplasty Registry 2013, The Danish Knee Registry 2015), 
with the fast-track protocol being considered the standard of 
care and no selection bias when reporting to the LCDB (Jor-
gensen and Kehlet 2013).  Furthermore, our cohort included 
patients who received VKA treatment on a wide range of indi-
cations, such as heart valves and genetic predisposition for 
VTE, in contrast to other recent studies—which have focused 
on patients with atrial fibrillation (Douketis et al. 2015a, b). 
Thus, our results reflect modern clinical practice in unselected 
THA and TKA patients. Finally, instead of using diagnostic 
codes, we reviewed the discharge papers of all patients with a 
lenght of stay of > 4 days or 30-day re-admissions, followed 
by review of the complete medical record in case of recorded 
thromboembolic or bleeding episodes. This approach may be 
superior to relying on administrative data or diagnostic codes 
(Severinsen et al. 2010, van Walraven et al. 2011).
In conclusion, no statistically significant differences in TE, 
VTE, or MB were found in preoperatively bridged and paused 
VKA patients after fast-track THA and TKA. However, the 
higher number of thromboembolic events in paused patients 
and of MBs in bridged patients warrants further large-scale 
investigation of indications for and optimal dosing of preop-
erative bridging with LMWH.
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